 |
Current Protocols in Molecular Biology
Featured Protocol
This
Featured Protocol presents a cutting-edge method excerpted from
Current Protocols in Molecular Biology UNIT 20.1.
From
UNIT 20.1
Interaction
Trap/Two-Hybrid System to Identify Interacting Proteins
Contributed
by Erica A. Golemis and Ilya Serebriiskii
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Russell
L. Finley. Jr. and Mikhail G. Kolonin
(hunt by interaction mating)
Wayne State University School of Medicine
Detroit, Michigan
Jeno
Gyuris
Mitotix, Inc.
Cambridge, Massachusetts
Roger
Brent
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts
To understand the function of a particular protein,
it is often useful to identify other proteins with which it associates.
This can be done by a selection or screen in which novel proteins
that specifically interact with a target protein of interest are
isolated from a library. One particularly useful approach to detect
novel interacting proteins--the two-hybrid system or interaction
trap (see Figs. 20.1.1 and 20.1.2)--uses
yeast as a "test tube" and transcriptional activation
of a reporter system to identify associating proteins (see Background
Information). This approach can also be used specifically to test
complex formation between two proteins for which there is a prior
reason to expect an interaction.
In the basic version of this method (see Fig.
20.1.2), the plasmid pEG202 or a related vector (see Fig.
20.1.3 and Table 20.1.1) is used to
express the probe or "bait" protein as a fusion to the
heterologous DNA-binding protein LexA. Many proteins, including
transcription factors, kinases, and phosphatases, have been successfully
used as bait proteins. The major requirements for the bait protein
are that it should not be actively excluded from the yeast nucleus,
and it should not possess an intrinsic ability to strongly activate
transcription. The plasmid expressing the LexA-fused bait protein
is used to transform yeast possessing a dual reporter system responsive
to transcriptional activation through the LexA operator. In one
such example, the yeast strain EGY48 contains the reporter plasmid
pSH18-34. In this case, binding sites for LexA are located upstream
of two reporter genes. In the EGY48 strain, the upstream activating
sequences of the chromosomal LEU2 gene--required in the biosynthetic
pathway for leucine (Leu)--are replaced with LexA operators (DNA
binding sites). pSH18-34 contains a LexA operator-lacZ fusion
gene. These two reporters allow selection for transcriptional
activation by permitting selection for viability when cells are
plated on medium lacking Leu, and discrimination based on color
when the yeast is grown on medium containing Xgal (UNIT 13.6).
In Basic Protocol 1, EGY48/pSH18-34 transformed
with a bait is characterized for its ability to express protein
(Support Protocol 1), growth on medium lacking Leu, and for the
level of transcriptional activation of lacZ (see Fig.
20.1.2A). A number of alternative strains, plasmids, and strategies
are presented which can be employed if a bait proves to have an
unacceptably high level of background transcriptional activation.
In an interactor hunt (Basic Protocol 2), the strain
EGY48/pSH18-34 containing the bait expression plasmid is transformed
(along with carrier DNA made as described in Support Protocol
2) with a conditionally expressed library made in the vector pJG4-5
(see Fig. 20.1.6).
This library uses the inducible yeast GAL1 promoter to express
proteins as fusions to an acidic domain ("acid blob")
that functions as a portable transcriptional activation motif
(act) and to other useful moieties. Expression of library-encoded
proteins is induced by plating transformants on medium containing
galactose (Gal), so yeast cells containing library proteins that
do not interact specifically with the bait protein will fail to
grow in the absence of Leu (see Fig. 20.1.2B).
Yeast cells containing library proteins that interact with the
bait protein will form colonies within 2 to 5 days, and the colonies
will turn blue when the cells are streaked on medium containing
Xgal (see Fig. 20.1.2C). The DNA from
interaction trap positive colonies can be analyzed by polymerase
chain reaction (PCR) to streamline screening and detect redundant
clones in cases where many positives are obtained in screening
(see Alternate Protocol 1). The plasmids are isolated and characterized
by a series of tests to confirm specificity of the interaction
with the initial bait protein (Support Protocols 3 to 5). Those
found to be specific are ready for further analysis (e.g., sequencing).
BASIC PROTOCOL 1 CHARACTERIZING A BAIT PROTEIN
The first step in an interactor hunt is to construct a plasmid
that expresses LexA fused to the protein of interest. This construct
is transformed into reporter yeast strains containing LEU2 and
lacZ reporter genes, and a series of control experiments is performed
to establish whether the construct is suitable as is or must be
modified, and whether alternative yeast reporter conditions should
be used. These controls establish that the bait protein is made
as a stable protein in yeast, that it is capable of entering the
nucleus and binding LexA operator sites, and that it does not
appreciably activate transcription of the LexA operator-based
reporter genes. This last is the most important constraint on
use of this system. The LexA-fused bait protein must not activate
transcription of either reporter-- the EGY48 strain (or related
strain EGY191) that expresses the LexA fusion protein should not
grow on medium lacking Leu, and the colonies should be white on
medium containing Xgal. The characterized bait protein plasmid
is used for Basic Protocol 2 to screen a library for interacting
proteins.
NOTE: All solutions and equipment coming into contact
with cells must be sterile, and proper sterile technique should
be used accordingly.
Materials
-
DNA encoding the protein of interest
-
Plasmids (see Table 20.1.1):
pEG202 (see Fig. 20.1.3), pSH18-34
(see Fig. 20.1.4), pSH17-4, pRFHM1,
and pJK101 for basic characterization; other plasmids for
specific circumstances as described (Clontech, Invitrogen,
Origene, or R.Brent)
-
Yeast strain EGY48 (ura3 trp1 his3 3LexA-operator-LEU2),
or EGY191 (ura3 trp1 his3 1LexA-operator-LEU2; Table
20.1.2)
-
Complete minimal (CM) medium dropout plates
(UNIT 13.1), supplemented with 2% (w/v) of the indicated sugars
(glucose or galatose), in 100-mm plates:
-
Glu/CM, -Ura, -His
-
Gal/CM, -Ura, -His
-
Gal/CM, -Ura, -His, -Leu
-
Z buffer (UNIT 13.6) with 1 mg/ml Xgal
-
Gal/CM dropout liquid medium (UNIT 13.1) supplemented
with 2% Gal
-
Antibody to LexA or fusion domain: monoclonal
antibody to LexA (Clontech, Invitrogen) or polyclonal antibody
to LexA (available from R. Brent or E. Golemis)
-
H2O, sterile
-
30°C incubator
-
Nylon membrane
-
Whatman 3MM filter paper
-
Additional reagents and equipment for subcloning
DNA fragments (UNIT 3.16), lithium acetate transformation
of yeast (UNIT 13.7), liquid assay b-galactosidase (UNIT 13.6),
preparation of protein extracts for immunoblot analysis (see
Support Protocol 1), and immunoblotting and immunodetection
(UNIT 10.8)
-
NOTE: All solutions and equipment coming into
contact with cells must be sterile, and proper sterile technique
should be used accordingly.
Transform yeast with the bait protein plasmid
-
Using standard subcloning techniques (UNIT 3.16),
insert the DNA encoding the protein of interest into the polylinker
of pEG202 (see Fig. 20.1.3) or
other LexA fusion plasmid to make an in-frame protein fusion.
The LexA fusion protein is expressed from
the strong alcohol dehydrogenase (ADH) promoter. pEG202
also contains a HIS3 selectable marker and a 2µm origin
for propagation in yeast. pEG202 with the DNA encoding the
protein of interest inserted is designated pBait. Uses of
alternative LexA fusion plasmids are described in Background
Information.
-
Perform three separate lithium acetate transformations
(UNIT 13.7) of EGY48 using the following combinations of plasmids:
-
pBait + pSH18-34 (test)
-
pSH17-4 + pSH18-34 (positive control for
activation)
-
pRFHM1 + pSH18-34 (negative control for
activation).
Use of the two LexA fusions as positive
and negative controls allows a rough assessment of the
transcriptional activation profile of LexA bait proteins.
pEG202 itself is not a good negative control because
the peptide encoded by the uninterrupted polylinker
sequences is itself capable of very weakly activating
transcription.
pSH18-34 contains a 2µm origin and a URA3
selectable marker for maintenance in yeast, as well
as a bacterial origin of replication and ampicillin-resistance
gene. It is the most sensitive LacZ reporter available
and will detect any potential ability to activate LacZ
transcription. pSH17-4 is a HIS3 2µm plasmid encoding
LexA fused to the activation domain of the yeast activator
protein GAL4. This fusion protein strongly activates
transcription. pRFHM1 is a HIS3 2µm plasmid encoding
LexA fused to the N-terminus of the Drosophila protein
bicoid. This fusion protein has no ability to activate
transcription.
-
Plate each transformation mixture on Glu/CM
-Ura, -His dropout plates. Incubate 2 days at 30°C to select
for yeast that contain both plasmids.
Colonies obtained can be used simultaneously
in tests for the activation of lacZ (steps 4 to 7) and LEU2
(steps 12 to 13) reporters.
Assay lacZ gene activation by b-galactosidase assay
-
Streak a Glu/CM -Ura, -His master dropout plate
with at least five or six independent colonies obtained from
each of the three transformations in step 3 (test, positive
control, and negative control) and incubate overnight at 30°C.
The filter assay described in Steps 5a to 7a (based on Breeden
and Nasmyth, 1985) provides a rapid assay for b-galactosidase
transcription. Alternatively, a liquid assay (UNIT 13.6) or
a plate assay (described in Steps 5b to 7b) may be used.
Perform filter assay for b-galactosidase activity:
-
a. Lift colonies by gently placing a nylon membrane
on the yeast plate and allowing it to become wet through.
Remove the membrane and air dry 5 min. Chill the membrane,
colony side up, 10 min at -70°C.
Whatman 3MM filters can be cut to the size of the yeast plate
as a more economical alternative to nylon membranes for performing
lifts. In addition, two or three 5-min temperature cycles
(-70°C to room temperature) can be used instead of a single
cycle to promote better lysis; this may be worth doing if
there is difficulty visualizing blue color.
-
a. Cut a piece of Whatman 3MM filter paper slightly
larger than the colony membrane and soak it in Z buffer containing
1 mg/ml Xgal. Place colony membrane, colony side up, on Whatman
3MM paper, or float it in the lid of a petri dish containing
~2 ml Z buffer with 1 mg/ml Xgal.
Acceptable results may be obtained using as little as 300
µg/ml Xgal.
-
a. Incubate at 30°C and monitor for color changes.
It is generally useful to check the membrane after 20 min,
and again after 2 to 3 hr. Strong activators will produce
a blue color in 5 to 10 min, and a bait protein (LexA fusion
protein) that does so is unsuitable for use in an interactor
hunt using this lacZ reporter plasmid. Weak activators will
produce a blue color in 1 to 6 hr (compare versus negative
control pRFHMI which will itself produce a faint blue color
with time) and may or may not be suitable. Weak activators
should be tested using the repressor assay described in steps
8 to 11.
Perform Xgal plate assay for lacZ activation:
-
b. Prepare Xgal plates as described in UNIT
13.1.
For activation assays, plates should be prepared with glucose
as a sugar source. For repression assays (steps 8 to 11),
galactose should be used as a sugar source. In our experience,
when patching from a master plate to Xgal plates, sufficient
yeast are transferred that plasmid loss is not a major problem
even in the absence of selection; this is balanced by the
desire to assay sets of constructs on the same plate to eliminate
batch variation in Xgal potency. Hence, plates should be made
either with complete minimal amino acid mix, or by dropping
out only uracil (-Ura), to make the plates universally useful.
-
b. Streak yeast from master plate to Xgal plate
and incubate at 30°C.
-
b. Examine plates for color development at intervals
over the next 2 to 3 days.
Strongly activating fusions should be visibly blue on the
plate within 12 to 24 hr; moderate activators will be visibly
blue after ~2 days.
When a bait protein appreciably activates transcription
under these conditions, there are several recourses. The first
and simplest is to switch to a less sensitive lacZ reporter
plasmid; use of pJK103 and pRB1840 may be sufficient to reduce
background to manageable levels. If this fails to work, it
is frequently possible to generate a truncated LexA fusion
that does not activate transcription.
Confirm fusion-protein synthesis by repression assay
For LexA fusions that do not activate transcription,
confirm by performing a repression assay (Brent and Ptashne, 1984)
that the LexA fusion protein is being synthesized in yeast (some
proteins are not) and that it is capable of binding LexA operator
sequences (Figure 20.1.5). The following
steps can be performed concurrently with the activation assay.
-
Transform EGY48 yeast with the following combinations
of plasmids (three transformations):
-
pBait + pJK101 (test)
-
pRFHM1 + pJK101 (positive control for repression)
-
pJK101 alone (negative control for repression).
-
Plate each transformation mix on Glu/CM -Ura,
-His dropout plates or Glu/CM -Ura dropout plates as appropriate
to select yeast cells that contain the indicated plasmids.
Incubate 2 to 3 days at 30°C until colonies appear.
-
Streak colonies to a Glu/CM -Ura, -His or Glu/CM
-Ura dropout master plate and incubate overnight at 30°C.
-
Assay b-galactosidase activity of the three
transformed strains (test, positive control, and negative
control) by liquid assay (using liquid Gal/CM dropout medium),
filter assay (steps 5a to 7a, first restreaking to Gal/CM
plates to grow overnight), or plate assay (steps 5b to 7b,
using Gal/CM -Ura XGal plates).
This assay should not be run for more than
1 to 2 hr for membranes, or 36 hr for Xgal plates, as the
high basal lacZ activity will make differential activation
of pJK101 impossible to see with longer incubations. Use
of Xgal plates, and inspection 12 to 24 hr after streaking,
is generally most effective.
The plasmid pJK101 contains the GAL upstream
activating sequence (UAS) followed by lexA operators upstream
of the lacZ coding sequence. Thus, yeast containing pJK101
will have significant b-galactosidase activity when grown
on medium in which Gal is the sole carbon source because
of binding of endogenous yeast GAL4 to the GALUAS.
LexA-fused proteins that are made, enter the nucleus, and
bind the lexA operator sequences block activation from the
GALUAS, repressing b-galactosidase activity 3-
to 20-fold. Note that on Glu/Xgal medium, yeast containing
pJK101 should be white, because GALUAS transcription
is repressed.
-
If a bait protein neither activates nor represses
transcription, perform immunoblot analysis by probing an immunoblot
of a crude lysate with antibodies against LexA or the fusion
domain to test for protein synthesis (see Support Protocol
1).
Even if a bait protein represses transcription,
it is generally a good idea to assay for the production
of full-length LexA fusions, as occasionally some fusion
proteins will be proteolytically cleaved by endogenous yeast
proteases. If the protein is made but does not repress,
it may be necessary to clone the sequence into a LexA fusion
vector that contains a nuclear localization motif, e.g.,
pJK202 (see Table 20.1.1), or to modify
or truncate the fusion domain to remove motifs that target
it to other cellular compartments (e.g., myristoylation
signals).
Test for Leu requirement
These steps can be performed concurrently with
the lacZ activation and repression assays.
-
Disperse a colony of EGY48 containing pBait
and pSH18-34 reporter plasmids into 500 ml sterile water.
Dilute 100 ml of suspension into 1 ml sterile water. Make
a series of 1/10 dilutions in sterile water to cover a 1000-fold
concentration range.
-
Plate 100 ml from each tube (undiluted, 1/10,
1/100, and 1/1000) on Gal/CM -Ura, -His dropout plates and
on Gal/CM -Ura, -His, -Leu dropout plates. Incubate overnight
at 30°C.
There will be a total of eight plates. Gal/CM
-Ura, -His dropout plates should show a concentration range
from 10 to 10,000 colonies and Gal/CM -Ura, -His, -Leu dropout
plates should have no colonies.
Actual selection in the interactor hunt is based
on the ability of the bait protein and acid-fusion pair, but
not the bait protein alone, to activate transcription of the
LexA operator-LEU2 gene and allow growth on medium lacking
Leu. Thus, the test for the Leu requirement is the most important
test of whether the bait protein is likely to have an unworkably
high background. The LEU2 reporter in EGY48 is more sensitive
than the pSH18-34 reporter for some baits, so it is possible
that a bait protein that gives little or no signal in a b-galactosidase
assay would nevertheless permit some level of growth on -Leu
medium. If this occurs, there are several options for proceeding,
the most immediate of which is to substitute EGY191(see Table
20.1.2), a less sensitive screening strain, and repeat
the assay.
As outlined in this protocol, the authors recommend
the strategy of performing the initial screening using the
most sensitive reporters and then, if activation is detected,
screening with increasingly less sensitive reporters (see
Critical Parameters for further discussion).
Table 20.1.1 Interaction
Trap Componentsa,b
|
Plasmid
|
Selection
|
Comments
|
|
name/source
|
In yeast
|
In E. coli
|
|
|
LexA fusion plasmids
|
|
|
|
pEG202c,d,e
|
HIS3
|
Apr
|
|
|
pJK202
|
HIS3
|
Apr
|
Like pEG202, but incorporates nuclear localization
sequences between LexA and polylinker; used to enhance
translocation of bait to nucleus
|
|
pNLexA
|
HIS3
|
Apr
|
Contains an ADH promoter that expresses
polylinker followed by LexA; used with baits where amino-terminal
residues must remain unblocked
|
|
pGildad
|
HIS3
|
Apr
|
Contains a GAL1 promoter that expresses
same LexA and polylinker cassette as pEG202; for use with
baits whose continuous presence is toxic to yeast
|
|
pEE202I
|
HIS3
|
Apr
|
An integrating form of pEG202 that can be
targeted into HIS3 following digestion with KpnI; used
where physiological screen requires lower levels of bait
to be expressed
|
|
pRFHM1e,f
(control)
|
HIS3
|
Apr
|
Contains an ADH promoter that expresses
LexA fused to the homeodomain of bicoid to produce nonactivating
fusion; used as positive control for repression assay,
negative control for activation and interaction assays
|
|
pSH17-4e,f
(control)
|
HIS3
|
Apr
|
ADH promoter expresses LexA fused to GAL4
activation domain; used as a positive control for transcriptional
activation
|
|
pMW101f
|
HIS3
|
Cmr
|
Same as pEG202, but with altered antibiotic
resistance markers; basic plasmid used for cloning bait
|
|
pMW103f
|
HIS3
|
Kmr
|
Same as pEG202, but with altered antibiotic
resistance markers; basic plasmid used for cloning bait
|
|
pHybLex/Zeof,g
|
Zeor
|
Zeor
|
Bait cloning vector compatible with
interaction trap and all other two-hybrid systems; minimal
ADH promotor expresses LexA followed by extended polylinker
|
|
Activation domain
fusion plasmids
|
|
|
|
pJG4-5c,d,e,f
|
TRP1
|
Apr
|
Contains a GAL1 promoter expresses nuclear
localization domain, transcriptional activation domain,
HA epitope tag, cloning sites; used to express cDNA libraries
|
|
pJG4-5I
|
TRP1
|
Apr
|
An integrating form of pJG4-5 that can be
targeted into TRP1 by digestion with Bsu36I (New England
Biolabs); to be used with pEE202I to study interactions
that occur physiologically at low protein concentrations
|
|
pYESTrpg
|
TRP1
|
Apr
|
Contains a GAL1 promoter that expresses
nuclear localization domain, transcriptional activation
domain, V5 epitope tag, multiple cloning sites; contains
f1 ori and T7 promoter/flanking site; used to express
cDNA libraries (Invitrogen)
|
|
pMW102f
|
TRP1
|
Kmr
|
Same as pJG4-5, but with altered antibiotic
resistance markers; no libraries yet available
|
|
pMW104f
|
TRP1
|
Cmr
|
Same as pJG4-5, but with altered antibiotic
resistance markers; no libraries yet available
|
|
LacZ reporter plasmids
|
|
|
|
pSH18-34d,e,f
|
URA3
|
Apr
|
Contains eight LexA operators that
direct transcription of the lacZ gene; one of the most
sensitive indicator plasmids for transcriptional activation
|
|
pJK103e
|
URA3
|
Apr
|
Contains two LexA operators that direct
transcription of the lacZ gene; an intermediate reporter
for transcriptional activation
|
|
pRB1840e
|
URA3
|
Apr
|
Contains one LexA operator that directs
transcription of the lacZ gene; one of the most stringent
reporters for transcriptional activation
|
|
pMW112f
|
URA3
|
Kmr
|
Same as pSH18-34, but with
altered antibiotic resistance marker
|
|
pMW109f
|
URA3
|
Kmr
|
Same as pJK103, but with altered antibiotic
resistance marker
|
|
pMW111f
|
URA3
|
Kmr
|
Same as pRB1840, but with altered antibiotic
resistance marker
|
|
pMW107f
|
URA3
|
Cmr
|
Same as pSH18-34, but with altered antibiotic
resistance marker
|
|
pMW108f
|
URA3
|
Cmr
|
Same as pJK103, but with altered antibiotic
resistance marker
|
|
pMW110f
|
URA3
|
Cmr
|
Same as pRB1840, but with altered antibiotic
resistance marker
|
|
pJK101e,f
(control)
|
URA3
|
Apr
|
Contains a GAL1 upstream activating sequences
followed by two LexA operators followed by lacZ gene;
used in repression assay to assess bait binding to operator
sequences
|
All plasmids contain a 2mm origin for maintenance in yeast, as well
as a bacterial origin of replication, except where noted (pEE202I,
pJG4.5I).
bInteraction trap reagents represent the work of many contributors:
the original basic reagents were developed in the Brent laboratory
(Gyuris et al., 1993). Plasmids with altered antibiotic resistance
markers (all pMW plasmids) were constructed at Glaxo in Research
Triangle Park, N.C. (Watson et al., 1996). Plasmids and strains
for specialized applications have been developed by the following
individuals: E. Golemis, Fox Chase Cancer Center, Philadelphia,
Pa. (pEG202); J. Kamens, BASF, Worcester, Mass. (pJK202); cumulative
efforts of I. York, Dana-Farber Cancer Center, Boston, Mass. and
M. Sainz and S. Nottwehr, U. Oregon (pNLexA); D.A. Shaywitz, MIT
Center for Cancer Research, Cambridge, Mass. (pGilda); R. Buckholz,
Glaxo, Research Triangle Park, N.C. (pEE2021, pJG4-51); J. Gyuris,
Mitotix, Cambridge, Mass. (pJG4-5); S. Hanes, Wadsworth Institute,
Albany, N.Y. (pSH17-4); R.L. Finley, Wayne State University School
of Medicine, Detroit, Mich. (pRFHM1); S. Hanes, Wadsworth Institute,
Albany, N.Y. (pSH18-34); J. Kamens, BASF, Worcester, Mass. (pJK101,
pJK103); R. Brent, The Molecular Sciences Institute, Berkeley, Calif.
(pRB1840). Specialized plasmids not yet commercially available can
be obtained by contacting the Brent laboratory at (510) 647-0690
or brent@molsci.org, or the Golemis laboratory, (215) 728-2860 or
EA_Golemis@fccc.edu.
cSequence data are available for pEG202 (pLexA); accession number
pending.
dPlasmids commercially available from Clontech and OriGene; for
Clontech pEG202 is listed as pLexA, pJG4-5 as pB42AD, and pSH18-34
as p8op-LacZ.
ePlasmids and strains available from OriGene.
fIn pMW plasmids the ampicillin resistance gene (Apr) is replaced
with the chloramphenicol resistance gene (Cmr) and the kanamycin
resistance gene (Kmr) from pBC SK(+) and pBK-CMV (Stratagene), respectively.
The choice between Kmr and Cmr or Apr plasmids is a matter of personal
taste; use of basic Apr plasmids is described in the basic protocols.
Use of the more recently developed reagents would facilitate the
purification of library plasmid in later steps by eliminating the
need for passage through KC8 bacteria, with substantial saving of
time and effort. Apr has been maintained as marker of choice for
the library plasmid because of the existence of multiple libraries
already possessing this marker. These plasmids are the basic set
of plasmids recommended for use.
gPlasmids commercially available from Invitrogen as components of
a Hybrid Hunter kit; this kit also includes all necessary positive
and negative controls (not listed in this table). See Background
Information for further details on commercially available reagents.
Table 20.1.2 Interaction Trap Yeast Selection Strainsa
| Strain |
Relevant genotype
|
Number of
operators |
Comments/description |
|
EGY48b,c,d
|
MATatrp1, his3, ura3, lexAops-LEU2 |
6 |
Contains LexA operators that direct transcription from
the LEU2 gene; basic strain used to select for interacting
clones from a cDNA library |
| EGY191 |
MATatrp1, his3, ura3, lexAops-LEU2 |
2 |
Provides a more stringent selection than EGY48, producing
lower background with baits with instrinsic ability to
activate transcription
|
| L40c |
MATatrp1, leu2, ade2, GAL4, lexAops-HIS34, lexAops-lacZ8 |
|
Expression driven from GAL1 promoter is constitutive in
L40 (inducible in EGY strains); selection is for HIS prototrophy.
Integrated lacZ reporter is considerably less sensitive
than pSH18-34 maintained in EGY strains |
aInteraction trap reagents represent the work of many
contributors; the original basic reagents were developed in the
Brent laboratory (Gyuris et al., 1993). Strains for specialized
applications have been developed by the following individuals: E.
Golemis, Fox Chase Cancer Center, Philadelphia, Pa. (EGY48, EGY191);
A.B. Vojtek and S.M. Hollenberg, Fred Hutchinson Cancer Research
Center, Seattle, Wash. (L40). Specialized strains not yet commercially
available can be obtained by contacting the Brent laboratory at
The Molecular Sciences Institute, Berkeley, (510) 647-0690 or brent@molsci.org,
or the Golemis laboratory, (215) 728-2860 or EA_Golemis@fccc.edu.
bStrains commercially available from Clontech.
cStrains commercially available from Invitrogen as components
of a Hybrid Hunter kit; the kit also includes all necessary positive
and negative controls (not listed in this table). See Background
Information for further details on commercially available reagents.
dStrains commercially available from OriGene |